27 completed. 19 Phase 1, 3 Not applicable, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 19 |
| Not applicable | 3 | Completed 3 |
| Phase 4 | 3 | Completed 3 |
Follow Drug Interaction Potentiation: new trials by email Literature Review of Drug Interaction Potentiation trials Research Report on Drug Interaction Potentiation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac Ilaprazole, Aceclofenac - Drug Interaction Potentiation | Phase 1 | Completed | Il-Yang Pharm. Co., Ltd. | 24 | 2022-11-10 | 2023-06-28 |
| Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole Ilaprazole, Naproxen, Aceclofenac - Drug Interaction Potentiation | Phase 1 | Completed | Il-Yang Pharm. Co., Ltd. | 72 | 2022-02-17 | 2023-06-28 |
| Doravirine, Rifapentine and Isoniazid Interaction Doravirine (DOR), Rifapentine (RPT), Isoniazid (INH) - Latent Tuberculosis, Human Immunodeficiency Virus | Phase 1 | Completed | Walter K. Kraft | 11 | 2019-04-22 | 2020-03-27 |
| Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan elbasvir/grazoprevir - Drug Interaction Potentiation | Completed | National Cheng-Kung University Hospital | 400 | 2018-10-22 | 2019-03-13 | |
| Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat Vadadustat, Rabeprazole - Drug Interaction Potentiation, Pharmacokinetics | Phase 1 | Completed | Akebia Therapeutics | 20 | 2018-10-03 | 2019-03-22 |
| Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Vadadustat, Furosemide, Adefovir - Drug Interaction Potentiation | Phase 1 | Completed | Akebia Therapeutics | 62 | 2018-07-20 | 2019-03-22 |
| Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin vadadustat, Rifampin, Probenecid - Drug Interaction Potentiation | Phase 1 | Completed | Akebia Therapeutics | 40 | 2018-07-20 | 2019-03-22 |
| Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin Vadadustat, Simvastatin, Rosuvastatin - Drug Interaction Potentiation | Phase 1 | Completed | Akebia Therapeutics | 134 | 2018-06-17 | 2019-03-22 |
| A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects Midazolam, Inarigivir - Drug Interaction Potentiation | Phase 1 | Completed | F-star Therapeutics, Inc. | 17 | 2018-05-07 | 2020-10-08 |
| Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor Mifepristone 300 MG, Itraconazole 100 MG - Drug Interaction Potentiation, Healthy | Phase 1 | Completed | Corcept Therapeutics | 33 | 2017-08-09 | 2018-02-22 |
| Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam LEO 32731, Midazolam - Drug Interaction Potentiation | Phase 1 | Completed | LEO Pharma | 32 | 2017-05-31 | 2017-11-14 |
| Improving Drug Safety in Emergency Patients -a Randomized Controlled Trial Medication reconciliation and medication review - Medication Compliance, Drug-Related Side Effects and Adverse Reactions | Not applicable | Completed | Diakonhjemmet Hospital | 806 | 2017-04-24 | 2023-02-21 |
| Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole Ilaprazole 10mg, Clarithromycin 500mg, Amoxicillin 500 Mg - Drug Interaction Potentiation | Phase 1 | Completed | Il-Yang Pharm. Co., Ltd. | 28 | 2016-12-01 | 2017-01-26 |
| Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1 intravenous infusion of 2 mg trospium chloride, oral administration of 30 mg trospium chloride, oral administration of 300 mg ranitidine - Pharmacokinetics, Inhibition Enzyme | Phase 1 | Completed | Dr. R. Pfleger Chemische Fabrik GmbH | 24 | 2016-11-01 | 2017-04-10 |
| A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects N91115, Rifampin - Drug Interaction Potentiation | Phase 1 | Completed | Nivalis Therapeutics, Inc. | 15 | 2015-06-01 | 2016-11-07 |
| Pharmacogenetic Testing Among Home Health Patients Pharmacogenetic testing - Adverse Drug Events, Adverse Drug Reactions | Not applicable | Completed | Genelex Corporation | 110 | 2015-03-01 | 2019-09-20 |
| Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg Dapoxetine 30mg, Mirodenafil 100mg - Drug Interaction Potentiation | Phase 1 | Completed | SK Chemicals Co., Ltd. | 36 | 2014-11-01 | 2015-06-30 |
| YouScript IMPACT Registry Adverse Drug Events, Adverse Drug Reactions | Completed | Genelex Corporation | 800 | 2014-10-01 | 2017-03-01 | |
| Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients Everolimus, Mycophenolate mofetil, Tacrolimus - Drug Interaction Potentiation | Phase 4 | Completed | National Taiwan University Hospital | 14 | 2014-04-01 | 2019-07-24 |
| Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg Dapoxetine 30mg tablet, Mirodenafil 50mg tablet - Drug Interaction Potentiation | Phase 1 | Completed | SK Chemicals Co., Ltd. | 36 | 2013-10-01 | 2015-06-30 |
Showing 20 of 27. Sign in to see all of them.
Drug-Related Side Effects and Adverse Reactions (3) · Drug Metabolism, Poor, CYP2C19-Related (2) · Drug Metabolism, Poor, CYP2D6-Related (2) · Acquired Immunodeficiency Syndrome (1) · Coronary Artery Disease (1) · Latent Tuberculosis (1) · Medication Adherence (1) · Myocardial Infarction (1) · Vitamin K-Dependent Clotting Factors, Combined Deficiency Of, Type 2 (1)
Chemically-Induced Disorders (3) · Cardiovascular Diseases (2) · Heart Diseases (2) · Myocardial Ischemia (2) · Vascular Diseases (2) · Actinomycetales Infections (1) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Coronary Disease (1) · Genital Diseases (1)
vadadustat (4) · ilaprazole (3) · Clarithromycin (2) · Digoxin (2) · Midazolam (2) · Ranitidine (2) · Rifampin (2) · Rosuvastatin Calcium (2) · aceclofenac (2) · dapoxetine (2) · mirodenafil (2) · Amoxicillin (1) · Atorvastatin (1) · Celecoxib (1) · Clopidogrel (1)
Akebia Therapeutics (4) · Il-Yang Pharm. Co., Ltd. (3) · Vifor Pharma (3) · Genelex Corporation (2) · SK Chemicals Co., Ltd. (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Corcept Therapeutics (1) · Diakonhjemmet Hospital (1) · Dr. R. Pfleger Chemische Fabrik GmbH (1) · F-star Therapeutics, Inc. (1) · LEO Pharma (1) · Medical University of Vienna (1) · National Cheng-Kung University Hospital (1) · National Taiwan University Hospital (1) · Nivalis Therapeutics, Inc. (1)
United States (8) · Canada (5) · South Korea (3) · Taiwan (2) · Austria (1) · China (1) · Germany (1) · Netherlands (1) · Norway (1)
Minsoo Park, PhD (2) · Ada Lee, MD (1) · Bernd Jilma, Prof. Dr. (1) · Christopher Galloway, MD (1) · Diana Brixner, PhD, RPh (1) · Jae-Wook Ko, MD, PhD (1) · Jeroen van de Wetering (1) · Lindsay Elliott, PharmD (1) · Manuela Koch, MD (1) · Meng-Kun Tsai (1) · Min MS Park, PhD (1)
PMID 26478982, PMID 26493304, PMID 27289472, PMID 28151991, PMID 28209466, PMID 29846770, PMID 31594667, PMID 36121830
2016 (1), 2018 (1)